RDUS (Radius Recycling, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RDUS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-08-15 | Chhaya Shah | Chief Business Officer | D | — | — |
| 2022-08-15 | Elizabeth Messersmith | Senior Vice President | D | — | — |
| 2022-08-15 | Danielle Holtschlag | Vice President, Sales | D | — | — |
| 2022-08-15 | Jennifer Jarrett | Director | D | — | — |
| 2022-08-15 | Susan Vissers Lisa | Director | D | — | — |
| 2022-08-15 | Sean Murphy | Director | U | — | — |
| 2022-08-15 | CATHY FRIEDMAN | Director | D | — | — |
| 2022-08-15 | Owen Hughes | Director | U | — | — |
| 2022-08-15 | JEAN PIERRE GARNIER | Director | MIXED | — | — |
| 2022-08-15 | ANDREW C. VON ESCHENBACH | Director | D | — | — |
| 2022-08-15 | G. Kelly Martin | CEO and President | D | — | — |
| 2022-08-15 | Willard H Dere | Director | MIXED | — | — |
| 2022-08-15 | MACHELLE SANDERS | Director | D | — | — |
| 2022-08-12 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2022-08-11 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2022-05-20 | Susan Vissers Lisa | Director | A | — | — |
| 2022-05-20 | Jennifer Jarrett | Director | A | — | — |
| 2022-05-20 | BB BIOTECH AG | 10%+ Owner | Buy | — | — |
| 2022-03-17 | Mark William Conley | VP, Chief Financial Officer | A | — | — |
| 2022-02-25 | G. Kelly Martin | CEO and President | A | — | — |
| 2022-02-23 | G. Kelly Martin | CEO and President | A | — | — |
| 2022-01-25 | Chhaya Shah | Chief Business Officer | A | — | — |
| 2022-01-25 | Danielle Holtschlag | Vice President, Sales | A | — | — |
| 2022-01-25 | Owen Hughes | Director | A | — | — |
| 2022-01-25 | Willard H Dere | Director | A | — | — |
| 2022-01-25 | Sean Murphy | Director | A | — | — |
| 2022-01-25 | ANDREW C. VON ESCHENBACH | Director | A | — | — |
| 2022-01-25 | JEAN PIERRE GARNIER | Director | A | — | — |
| 2022-01-25 | MACHELLE SANDERS | Director | A | — | — |
| 2022-01-25 | Steven Helwig | Principal Financial Officer | A | — | — |
| 2022-01-25 | CATHY FRIEDMAN | Director | A | — | — |
| 2022-01-07 | TARGET N V BIOTECH | 10%+ Owner | Buy | — | — |
| 2021-12-16 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2021-12-15 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2021-12-10 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2021-10-18 | Danielle Holtschlag | Vice President, Sales | A | — | — |
| 2021-10-01 | BB BIOTECH AG | 10%+ Owner | Buy | — | — |
| 2021-09-24 | BB BIOTECH AG | 10%+ Owner | Buy | — | — |
| 2021-09-23 | Chhaya Shah | Chief Business Officer | A | — | — |
| 2021-08-26 | Steven Helwig | Principal Financial Officer | A | — | — |
| 2021-03-24 | G. Kelly Martin | CEO and President | A | — | — |
| 2021-03-09 | James George Chopas | Principal Finance Accounting | Sell | — | — |
| 2021-02-26 | Sal Grausso | Chief Commercial Officer | Sell | — | — |
| 2021-02-23 | CATHY FRIEDMAN | Director | A | — | — |
| 2021-02-23 | G. Kelly Martin | CEO and President | A | — | — |
| 2021-02-23 | Sean Murphy | Director | A | — | — |
| 2021-02-23 | Owen Hughes | Director | A | — | — |
| 2021-02-23 | Sal Grausso | Chief Commercial Officer | A | — | — |
| 2021-02-23 | James George Chopas | Principal Finance Accounting | A | — | — |
| 2021-02-23 | Willard H Dere | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,733,538 | — |
| — | 10%+ Owner | 8,642,271 | — |
| — | 10%+ Owner | 8,255,714 | — |
| — | 10%+ Owner | 3,887,502 | — |
| — | Director | 3,887,502 | — |
| — | 10%+ Owner | 2,666,834 | — |
| — | — | 2,459,804 | — |
| — | — | 2,459,804 | — |
| — | 10%+ Owner | 1,427,698 | — |
| — | 10%+ Owner | 1,167,997 | — |
| — | Sr. VP and CFO | 76,189 | — |
| — | VP, Chief Financial Officer | 50,000 | — |
| — | Chief Financial Officer | 46,708 | — |
| — | Chief Medical Officer | 33,744 | — |
| — | Principal Financial Officer | 31,251 | — |
| — | Sr. VP of Sales and Marketing | 24,111 | — |
| — | Director | 18,300 | — |
| — | Sr. VP, General Counsel | 17,944 | — |
| — | President & CEO | 15,000 | — |
| — | President and CEO | 12,900 | — |
| — | Director | 12,401 | — |
| — | Chief Commercial Officer | 11,709 | — |
| — | Director | 11,000 | — |
| — | Principal Finance Accounting | 6,701 | — |
| — | Chief Commercial Officer | 6,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RDUS quote page; the site-wide leaderboard is on the insider transactions hub.